Gamma surgery for @entity320 XXXX in the brain.

@entity1 @entity75 @entity5 @entity16 @entity797 @entity3 @entity1104 @entity204 @entity320
OBJECT: The aim of this study was to evaluate the usefulness and limitations of @entity1104 ( @entity1104 ) in the treatment of brain @entity3 from @entity320 . METHODS: Imaging and clinical outcomes in 45 @entity1 treated for 92 brain @entity3 from @entity320 between October 1989 and October 1999 were retrospectively analyzed. Follow-up imaging studies were available in 35 @entity1 with 66 treated lesions. Twenty-four percent of the lesions disappeared, 35% shrank, 23% remained unchanged, and 18% increased in size. No undue radiation-induced changes were observed in the surrounding brain. Clinical data were available in all @entity1 . No @entity204 or @entity16 related to @entity1104 was observed. The median survival time, calculated using the Kaplan-Meier method, was 10.4 months from the time of @entity1104 . In both univariate and multivariate @entity797 regression analyses, a single @entity75 and lack of visceral @entity3 were statistically predictive of a better prognosis. Six of eight @entity1 with solitary metastasis (that is, a single brain metastasis with no primary @entity5 ) were still alive at the close of the study, none of them with disease progression, with a follow-up period ranging between 14 and 82 months. Sixteen @entity1 in this series received adjunctive whole-brain radiation therapy, which had no impact on their survival time or local and distant control of the @entity75 . CONCLUSIONS: Gamma surgery is effective in treating @entity320 @entity3 in the brain. It appears that the radiobiology of a single high dose overcomes the radioresistance barrier, yielding better results than fractionated radiation.
